Last reviewed · How we verify
NCT05255367: CARDIOGENE
Effect of (Poly)Phenolic on Cardiometabolic Risk of Postmenopausal Women
NA trial testing (poly)phenols rich foods in Post-menopausal Women in 26 participants. Completed in 1 July 2022.
1 July 2022
Quick facts
| Lead sponsor | Universidad de Murcia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 26 |
| Start date | 1 March 2022 |
| Primary completion | 1 July 2022 |
| Estimated completion | 1 July 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- (poly)phenols rich foods
Conditions studied
- Post-menopausal Women — all drugs for Post-menopausal Women →
- Overweight and Obesity — all drugs for Overweight and Obesity →
Sponsor
Universidad de Murcia — full company profile →
Who can join
Adults 45 to 65, female only, with Post-menopausal Women or Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this investigation is to test the hypothesis that in post-menopausal women with cardiometabolic risk, eating a relatively high daily amount of (poly)phenol-containing products (green tea, dark chocolate and berries) could reduce the risk of metabolic syndrome and cardiovascular disease. Changes in different biomarkers of lipid metabolism, glucose metabolism, inflammation and oxidative stress will be evaluated. Other related factors may be also affected, such as body mass index (BMI) and the percentage of body fat, dietary habits (total energy intake and macronutrient distribution) and microbiota composition.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Natural products targeting inflammation-related metabolic disorders: A comprehensive review.
Nainu F, Frediansyah A, Mamada SS, Permana AD, et al · · 2023 · cited 22× · PMID 37346355 · DOI 10.1016/j.heliyon.2023.e16919 -
Medicinal plants for the treatment and prevention of post-menopausal obesity: a review.
Liu J, Akter R, Rupa EJ, Van-An H, et al · · 2025 · cited 1× · PMID 40469982 · DOI 10.3389/fphar.2025.1564131
Verify or expand the search:
- PubMed search for NCT05255367
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Universidad de Murcia trials
Trials by the same sponsor.
- NCT07310459 — Perinatal Risk Factors in Motor Development · not yet recruiting
- NCT06982456 — Manual Therapy Techniques for Cervical Pain: Algometric Evaluation · NA · enrolling by invitation
- NCT06910150 — Effectiveness of a Session of Analgesic Electrostimulation (Invasive and Non-invasive) Applied to the Quadriceps Muscle · NA · enrolling by invitation
- NCT06206499 — Laterally Rotated Flap for Soft Tissue Augmentation Around Maxillary Loaded Osseointegrated Dental Implant · NA · unknown
- NCT06240416 — Autogenous Particles Harvesting During Implant Surgery · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05255367 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad de Murcia
- Last refreshed: 21 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05255367.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing